Last reviewed · How we verify
Gentamicin + narrow spectrum betalactam
Gentamicin and a narrow-spectrum beta-lactam antibiotic work synergistically to kill bacteria by inhibiting protein synthesis and disrupting cell wall integrity.
Gentamicin and a narrow-spectrum beta-lactam antibiotic work synergistically to kill bacteria by inhibiting protein synthesis and disrupting cell wall integrity. Used for Serious gram-negative bacterial infections, Empiric therapy for hospital-acquired infections, Febrile neutropenia in immunocompromised patients.
At a glance
| Generic name | Gentamicin + narrow spectrum betalactam |
|---|---|
| Sponsor | University Hospital, Akershus |
| Drug class | Aminoglycoside + Beta-lactam antibiotic combination |
| Target | Bacterial 30S ribosome (gentamicin); Penicillin-binding proteins (beta-lactam) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Gentamicin is an aminoglycoside that binds to bacterial ribosomes and inhibits protein synthesis, while the narrow-spectrum beta-lactam (such as a penicillin or cephalosporin) inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. This combination provides synergistic bactericidal activity, particularly effective against gram-negative aerobic bacteria and some gram-positive organisms, commonly used in empiric therapy for serious infections.
Approved indications
- Serious gram-negative bacterial infections
- Empiric therapy for hospital-acquired infections
- Febrile neutropenia in immunocompromised patients
Common side effects
- Nephrotoxicity
- Ototoxicity
- Allergic reaction (beta-lactam)
- Hypokalemia
- Nausea/vomiting
Key clinical trials
- Aminoglycosides in Early Sepsis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: